Rick S. Kent
Director/Board Member at Vascular Pharmaceuticals, Inc.
Profile
Rick S.
Kent currently works at Esanex, Inc., as Director, Innocrin Pharmaceuticals Holdings LLC, as Director, Vascular Pharmaceuticals, Inc., as Director, and Innocrin Pharmaceuticals, Inc., as Director.
Dr. Kent also formerly worked at Serenex, Inc., as President & Chief Executive Officer from 2002 to 2007, Ardent Pharmaceuticals, Inc., as President & Chief Executive Officer in 2002, Aldagen, Inc., as Chairman from 2010 to 2012, Nuo Therapeutics, Inc., as Independent Director from 2012 to 2014, Inspire Pharmaceuticals, Inc., as Director from 2004 to 2011, Cempra Pharmaceuticals, Inc., as Director, CSA Medical, Inc., as Director, Cempra, Inc., as Director from 2010 to 2011, Glaxo Wellcome, Inc., as VP-US Medical Affairs & Group Medical Director from 1998 to 2001, Burroughs Wellcome, as International Director-Medical Research, GSK Plc, as Chief Medical Officer & SVP-Global Medical Affairs, and Duke University, as Member-Medical Faculty.
Dr. Kent received his undergraduate degree from the University of California, Berkeley and doctorate degree from the University of California San Diego.
Rick S. Kent active positions
| Companies | Position | Start |
|---|---|---|
Vascular Pharmaceuticals, Inc.
 Vascular Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vascular Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of diabetics. It provides new treatment options to individuals living with diabetic complications such as nephropathy. The company was founded by David R. Clemmons and Laura Maile in 2005 and is headquartered in Research Triangle Park, NC. | Director/Board Member | - |
Esanex, Inc.
 Esanex, Inc. Pharmaceuticals: MajorHealth Technology Esanex, Inc. manufactures and develops drugs for cancer treatment. Its products include orally active Hsp90 inhibitors. The company was founded in 2011 and is headquartered in Indianapolis, IN. | Director/Board Member | - |
Innocrin Pharmaceuticals, Inc.
 Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Director/Board Member | - |
Innocrin Pharmaceuticals Holdings LLC
 Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Director/Board Member | - |
Former positions of Rick S. Kent
| Companies | Position | End |
|---|---|---|
| NUO THERAPEUTICS, INC. | Director/Board Member | 2014-12-30 |
Aldagen, Inc.
 Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Chairman | 2012-01-31 |
Inspire Pharmaceuticals, Inc.
 Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inspire Pharmaceuticals, Inc. operated as a biopharmaceutical company. It discovered and developed pharmaceutical products to treat diseases that results from deficiencies in the body's natural mechanisms of mucosal hydration. The company was founded by Kendall Harden, Richard C. Boucher, Andre L. Lamotte, H. Jefferson Leighton and Terrance G. McGuire and was headquartered in Whitehouse Station, NJ. | Director/Board Member | 2011-05-12 |
Serenex, Inc.
 Serenex, Inc. Pharmaceuticals: MajorHealth Technology Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC. | Chief Executive Officer | 2008-03-31 |
Ardent Pharmaceuticals, Inc.
 Ardent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ardent Pharmaceuticals, Inc. researches and develops drugs for pain, urinary incontinence, premature ejaculation, depression and cardio protection. The company is headquartered in New York, NY. | Chief Executive Officer | 2001-12-31 |
Training of Rick S. Kent
| University of California San Diego | Doctorate Degree |
| University of California, Berkeley | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GSK PLC | Health Technology |
| NUO THERAPEUTICS, INC. | Health Technology |
| Private companies | 13 |
|---|---|
Inspire Pharmaceuticals, Inc.
Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inspire Pharmaceuticals, Inc. operated as a biopharmaceutical company. It discovered and developed pharmaceutical products to treat diseases that results from deficiencies in the body's natural mechanisms of mucosal hydration. The company was founded by Kendall Harden, Richard C. Boucher, Andre L. Lamotte, H. Jefferson Leighton and Terrance G. McGuire and was headquartered in Whitehouse Station, NJ. | Health Technology |
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Health Technology |
Serenex, Inc.
Serenex, Inc. Pharmaceuticals: MajorHealth Technology Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC. | Health Technology |
| Glaxo Wellcome, Inc. | Health Technology |
| Burroughs Wellcome | |
Ardent Pharmaceuticals, Inc.
Ardent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ardent Pharmaceuticals, Inc. researches and develops drugs for pain, urinary incontinence, premature ejaculation, depression and cardio protection. The company is headquartered in New York, NY. | Health Technology |
Cempra Pharmaceuticals, Inc.
 Cempra Pharmaceuticals, Inc. BiotechnologyHealth Technology Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC. | Health Technology |
Cempra, Inc.
 Cempra, Inc. Pharmaceuticals: MajorHealth Technology Cempra, Inc. engages as a clinical-stage pharmaceutical company, which focuses on the development of antibacterials to meet critical medical needs. Its products include; Solithromycin and Taksta. The company was founded by Prabhavathi B. Fernandes on November 18, 2005 and is headquartered in Chapel Hill, NC. | Health Technology |
Vascular Pharmaceuticals, Inc.
Vascular Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vascular Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of diabetics. It provides new treatment options to individuals living with diabetic complications such as nephropathy. The company was founded by David R. Clemmons and Laura Maile in 2005 and is headquartered in Research Triangle Park, NC. | Health Technology |
Esanex, Inc.
Esanex, Inc. Pharmaceuticals: MajorHealth Technology Esanex, Inc. manufactures and develops drugs for cancer treatment. Its products include orally active Hsp90 inhibitors. The company was founded in 2011 and is headquartered in Indianapolis, IN. | Health Technology |
CSA Medical, Inc.
 CSA Medical, Inc. Medical SpecialtiesHealth Technology CSA Medical, Inc. develops endoscopic cryoablation systems. It provides spray cryotherapy medical device solutions that improve patient outcomes, simplify procedures, and reduce the cost of healthcare. The company was founded by Lloyd Shue, Timothy E. Askew and Frank Majerowicz in 1985 and is headquartered in Lexington, MA. | Health Technology |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Health Technology |
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Rick S. Kent